SonoSite Introduces Cardiology Capabilities for Titan at ACC; Fully Featured Hand-Carried Ultrasound System Provides Complete Capabilities for Echo Studies.

Business Editors & Health/Medical/Technology Writers

American College of Cardiology 53rd Annual Scientific Session

NEW ORLEANS--(BUSINESS WIRE)--March 8, 2004

New Capabilities Address $460 Million International

Shared Services Market

SonoSite, Inc. (Nasdaq:SONO), the worldwide leader in high-performance, hand-carried ultrasound, today announced at the American College of Cardiology (ACC) 53rd Annual Scientific Session that it is adding cardiology capabilities to the TITAN(TM) system, the company's newest generation, high-resolution, hand-carried system that enables ultrasound to be available quickly wherever and whenever it is needed. Customer deliveries are scheduled for mid-June; current customers will be able to upgrade to the enhanced TITAN system capabilities. SonoSite will be introducing these new TITAN capabilities in Booth #344 during ACC in New Orleans from March 7-10.

"SonoSite continues to develop technology that provides rapid, cost-effective and high-quality patient care," said Kevin M. Goodwin, president and CEO of SonoSite. "This release will enable physicians to use TITAN's high performance capabilities to perform full echocardiography and vascular studies in the clinic or at the point-of-care, allowing for earlier diagnosis and treatment. It also addresses the need of many of our international customers who require a shared service system that can perform both radiology and cardiology examinations. The shared service market is estimated to account for at least 20 percent of the $ 2.3 billion international ultrasound market."

The TITAN system is based on SonoSite's proprietary ASIC (Application Specific Integrated Circuit) technology, which integrates millions of transistors onto one circuit. The cardiology upgrade will offer full cardiac and vascular calculation packages, pulsed and steerable continuous wave Doppler, Tissue Harmonic Imaging, velocity-based color Doppler, M-Mode and image storage to compact flash cards and the ability to export video to storage devices. These features enable the user to perform echocardiography studies that meet the standards required by payers for a complete echocardiography examination. Weighing only 7.7 pounds (3.5 kg.), the TITAN system boots up in less than 12 seconds and can be easily carried to wherever it is needed to immediately deliver patient care efficiently and effectively.

Introduced in May 2003 for multiple imaging applications, the TITAN system has gained acceptance in both the United States and international markets. This is SonoSite's second major feature upgrade to TITAN. In December 2003, SonoSite began customer deliveries of a new software package for vascular imaging and expanded connectivity capabilities.

Cardiovascular disease is the leading cause of death across Europe, responsible for more than 2 million deaths each year in people 75 and younger. Moreover, according to the U.S. Department of Health and Human Services, it is estimated that more than 1 million Americans will also die of cardiovascular disease in 2004. Prompt and accurate diagnosis of cardiovascular disease is critical to improving a patient's prognosis.

About SonoSite

SonoSite, Inc. (www.sonosite.com), headquartered in Bothell, Wash., is the innovator and worldwide market leader in high-performance, hand-carried ultrasound technology. By creating modular, mobile systems that meet customer needs, SonoSite is removing barriers to the use of ultrasound across medicine and positively impacting the cost-effectiveness and efficiency of ultrasound use. With more than 14,000 units sold worldwide since 1999, SonoSite's products have become known for exceptional durability with a high design value.

Forward-looking Information and the Private Litigation Reform Act

of 1995

Certain statements in this press release relating to the market acceptance of our products, possible future sales relating to expected orders, and our future financial and operations results are "forward-looking statements" for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the opinions and estimates of our management at the time the statements are made and are subject to risks and uncertainties that could cause actual results to differ materially from those expected or implied by the forward-looking statements. These statements are not guaranties of future performance and are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions. Factors that could affect the rate and extent of market acceptance of our products, the receipt of expected orders, and our financial performance include our ability to accurately forecast customer demand for our products, our ability to manufacture and ship our systems in a timely manner to meet customer demand, timely receipts of regulatory approvals to market and sell our products, the willingness of healthcare providers who do not currently use ultrasound to use ultrasound, the extent to which healthcare insurers reimburse providers for ultrasound procedures, regulatory changes in various national health care markets, constraints in government and public health spending, the ability of our distribution partners to market and sell our products, as well as other factors described under the heading, "Important Factors that May Affect Our Business, Our Results of Operating and Our Stock Price," included in our latest periodic report filed with the Securities and Exchange Commission. We caution readers not to place undue reliance upon these forward-looking statements that speak only as to the date of this release. We undertake no obligation to publicly revise any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

TITAN is a trademark of SonoSite, Inc.